Loading…

Protocol - Transfusion Indications

Add to My Toolkit
Description

This protocol includes seven items from the Silent Cerebral Infarct Transfusion (SIT) Trial that capture the reason for transfusion, pre-transfusion laboratory results, pre-medications administered, the type of transfusion, and the volume transfused.

Specific Instructions

The Sickle Cell Disease Pregnancy Working Group (WG) acknowledges that the forms were developed for children ages 5-14 years but recommends that these forms can also be used for pregnant people with sickle cell disease. The WG further recommends that investigators also consider these related protocols: Prophylactic Transfusion during Pregnancy and Transfusion Reactions. Although there is some duplication among these protocols, they contain varying degrees of detail.

The WG removed an annotation in question 2d indicating that an adverse events form should be completed if there are neurological symptoms.

Availability

Available

Download PDF

Protocol

S31r4 Transfusion Form

Patients Identification Number                  ______________________________

Visit Date (yyyy/mm/dd):                            ______________________________

Correction:

[ ] Yes

[ ] No

1. Date of transfusion (yyyy/mm/dd)          _____________________________

2. Reason for transfusion

[ ] Scheduled

[ ] Non-Scheduled

2. If transfusion is non-scheduled, answer Items 2A through 2F.

2A. Acute chest syndrome

[ ] Yes

[ ] No

2B. Painful episode

[ ] Yes

[ ] No

2C. Multi-organ failure

[ ] Yes

[ ] No

2D. Neurological symptoms

[ ] Yes

[ ] No

2E. Surgery

[ ] Yes

[ ] No

2F. Other

[ ] Yes

[ ] No

2F-1. Please indicate other:                       _______________________________

3. Pre-transfusion laboratory results

3A. Hemoglobin S

[ ] Done

[ ] Not Done

3A-1. Date obtained (yyyy/mm/dd)         _______________________________

3A-2. Results (xxx.x %)                              _______________________________

3B. Ferritin

[ ] Done

[ ] Not Done

3B-1. Date obtained (yyyy/mm/dd)         _______________________________

3B-2. Results (xxxx.x ng/ml)                     ________________________________

3C. Hemoglobin level

[ ] Done

[ ] Not Done

3C-1. Date obtained (yyyy/mm/dd)         _______________________________

3C-2. Results (xx.x g/dl)                           ________________________________

4. Pre-medications administered:

4A. Tylenol

[ ] Yes

[ ] No

4B. Benadryl

[ ] Yes

[ ] No

4C. Claritin

[ ] Yes

[ ] No

4D. Other

[ ] Yes

[ ] No

4E. None given

[ ] Yes

[ ] No

5. Transfusion:

5. Simple transfusion

[ ] Done

[ ] Not Done

5A. Amount transfused (xxxx cc)           _______________________________

6. Modified manual exchange

[ ] Done

[ ] Not Done

6A. Amount removed (xxxx cc)             _______________________________

6B. Amount transfused (xxxx cc)            _______________________________

7. Pheresis

[ ] Done

[ ] Not Done

Staff I.D. #: ______________________

Personnel and Training Required

Personnel who are trained in performing medical records review.

Equipment Needs

None

Requirements
Requirement CategoryRequired
Major equipment No
Specialized training No
Specialized requirements for biospecimen collection No
Average time of greater than 15 minutes in an unaffected individual No
Mode of Administration

Medical record abstraction

Lifestage

Child, Adolescent, Adult, Pregnancy

Participants

Children and adults with sickle cell disease.

Selection Rationale

These items from the Silent Cerebral Infarct Transfusion (SIT) Trial are easy to administer, brief, and capture the necessary details relevant to red cell transfusion. This protocol came from the SIT Trial, a randomized controlled trial in a pediatric sickle cell disease population.

Language

English

Standards
StandardNameIDSource
Derived Variables

None

Process and Review

Not Applicable

Protocol Name from Source

Silent Cerebral Infarct Transfusion (SIT) Trial, S31r4 Transfusion Form

Source

DeBaun, M. R., Gordon, M., McKinstry, R. C., Noetzel, M. J., White, D. A., Sarnaik, S. A., Meier, E. R., Howard, T. H., Majumdar, S., Inusa, B. P., Telfer, P. T., Kirby-Allen, M., McCavit, T. L., Kamdem, A., Airewele, G., Woods, G. M., Berman, B., Panepinto, J. A., Fuh, B. R., Kwiatkowski, J. L., ? Casella, J. F. (2014). Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. The New England journal of medicine, 371(8), 699?710. https://doi.org/10.1056/NEJMoa1401731

Silent Cerebral Infarct Transfusion (SIT) Trial S31r4 Transfusion Form, Items 1?7.

General References

DeBaun, M. R., Sarnaik, S. A., Rodeghier, M. J., Minniti, C. P., Howard, T. H., Iyer, R. V., Inusa, B., Telfer, P. T., Kirby-Allen, M., Quinn, C. T., Bernaudin, F., Airewele, G., Woods, G. M., Panepinto, J. A., Fuh, B., Kwiatkowski, J. K., King, A. A., Rhodes, M. M., Thompson, A. A., Heiny, M. E., Redding-Lallinger, R. C., Kirkham, F. J., Sabio, H., Gonzalez, C. E., Saccente, S. L., Kalinyak, K. A., Strouse, J. J., Fixler, J. M., Gordon, M. O., Miller, J. P., Noetzel, M. J., Ichord, R. N., & Casella, J. F. (2012). Associated risk factors for silent cerebral infarcts in sickle cell anemia: Low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood, 119(16), 3684?3690. doi:10.1182/blood-2011-05-349621

Pan, H., Ives, C., Mandal, M., Qin, Y., Hendershot, T., Popovic, J., Brambilla, D., Stratford, J., Treadwell, M., Wu, X., & Kroner, B. (2022). CureSCi Metadata Catalog?Making sickle cell studies findable. PLOS ONE, 17(12), e0256248. https://doi.org/10.1371/journal.pone.0256248

Protocol ID

890401

Variables
Export Variables
Variable Name Variable IDVariable DescriptiondbGaP Mapping
PX890401_Transfusion_Indications_Acs
PX890401050000 Acute chest syndrome N/A
PX890401_Transfusion_Indications_Amount_Simple
PX890401190000 Amount transfused more
_______________________________ show less
N/A
PX890401_Transfusion_Indications_Correction
PX890401020000 Correction: N/A
PX890401_Transfusion_Indications_Date
PX890401010000 Visit Date: more
______________________________ show less
N/A
PX890401_Transfusion_Indications_Date_Ferritin
PX890401080000 Date obtained more
_______________________________ show less
N/A
PX890401_Transfusion_Indications_Date_Hemoglobin
PX890401110000 Date obtained more
_______________________________ show less
N/A
PX890401_Transfusion_Indications_Date_Hs
PX890401050800 Date obtained more
_______________________________ show less
N/A
PX890401_Transfusion_Indications_Date_Transfusion
PX890401030000 Date of transfusion more
_____________________________ show less
N/A
PX890401_Transfusion_Indications_Ferritin
PX890401070000 Ferritin N/A
PX890401_Transfusion_Indications_Hemoglobin
PX890401100000 Hemoglobin level N/A
PX890401_Transfusion_Indications_Hemoglobin_S
PX890401050700 Hemoglobin S N/A
PX890401_Transfusion_Indications_Mme_Simple
PX890401200000 Modified manual exchange N/A
PX890401_Transfusion_Indications_Mof
PX890401050200 Multi-organ failure N/A
PX890401_Transfusion_Indications_Neuro_Symptom
PX890401050300 Neurological symptoms N/A
PX890401_Transfusion_Indications_Other
PX890401050500 Other N/A
PX890401_Transfusion_Indications_Other_Desc
PX890401050600 Please indicate other: more
_______________________________ show less
N/A
PX890401_Transfusion_Indications_Pain
PX890401050100 Painful episode N/A
PX890401_Transfusion_Indications_Pheresis
PX890401230000 Pheresis N/A
PX890401_Transfusion_Indications_Pre_Medication_Benadryl
PX890401140000 Pre-medications administered: Benadryl N/A
PX890401_Transfusion_Indications_Pre_Medication_Claritin
PX890401150000 Pre-medications administered: Claritin N/A
PX890401_Transfusion_Indications_Pre_Medication_None
PX890401170000 Pre-medications administered: None given N/A
PX890401_Transfusion_Indications_Pre_Medication_Other
PX890401160000 Pre-medications administered: Other N/A
PX890401_Transfusion_Indications_Pre_Medication_Tylenol
PX890401130000 Pre-medications administered: Tylenol N/A
PX890401_Transfusion_Indications_Reason
PX890401040000 Reason for transfusion N/A
PX890401_Transfusion_Indications_Removed_Simple
PX890401210000 Amount removed more
_______________________________ show less
N/A
PX890401_Transfusion_Indications_Results_Ferritin
PX890401090000 Results more
________________________________ show less
N/A
PX890401_Transfusion_Indications_Results_Hemoglobin
PX890401120000 Results more
________________________________ show less
N/A
PX890401_Transfusion_Indications_Results_Hs
PX890401060000 Results more
_______________________________ show less
N/A
PX890401_Transfusion_Indications_Simple
PX890401180000 Simple transfusion N/A
PX890401_Transfusion_Indications_Surgery
PX890401050400 Surgery N/A
PX890401_Transfusion_Indications_Transfused_Simple
PX890401220000 Amount transfused more
_______________________________ show less
N/A
SCD Pregnancy
Measure Name

Transfusion Indications

Release Date

August 5, 2024

Definition

Blood transfusion is an important therapeutic intervention in both children and adults with sickle cell disease. 

Purpose

Transfusion therapy is used to treat and prevent sickle cell disease (SCD) complications. Transfusion in pregnant people with SCD, in the right context, may reduce maternal mortality, vaso-occlusive pain events, and pulmonary complications, as well as pre-term birth and perinatal mortality, but must be used judiciously in consultation with hematology to balance its risks.

Keywords

sickle cell disease, SCD, transfusion, blood transfusion, red cell transfusion, exchange transfusion, simple transfusion, pregnancy, Silent Cerebral Infarct Transfusion (SIT) Trial

Measure Protocols
Protocol ID Protocol Name
890401 Transfusion Indications
Publications

There are no publications listed for this protocol.